X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs TORRENT PHARMA - Comparison Results

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA TORRENT PHARMA ELDER PHARMA/
TORRENT PHARMA
 
P/E (TTM) x -0.2 44.3 - View Chart
P/BV x 0.1 6.3 1.6% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 ELDER PHARMA   TORRENT PHARMA
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
TORRENT PHARMA
Mar-18
ELDER PHARMA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs3801,550 24.5%   
Low Rs1881,144 16.4%   
Sales per share (Unadj.) Rs491.2354.7 138.5%  
Earnings per share (Unadj.) Rs-3.240.1 -7.9%  
Cash flow per share (Unadj.) Rs14.464.2 22.4%  
Dividends per share (Unadj.) Rs014.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs376.5273.1 137.8%  
Shares outstanding (eoy) m20.54169.22 12.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.63.8 15.2%   
Avg P/E ratio x-89.333.6 -265.6%  
P/CF ratio (eoy) x19.721.0 94.0%  
Price / Book Value ratio x0.84.9 15.3%  
Dividend payout %034.9 0.0%   
Avg Mkt Cap Rs m5,833227,897 2.6%   
No. of employees `000NA14.7 0.0%   
Total wages/salary Rs m2,17911,353 19.2%   
Avg. sales/employee Rs ThNM4,083.0-  
Avg. wages/employee Rs ThNM772.3-  
Avg. net profit/employee Rs ThNM461.3-  
INCOME DATA
Net Sales Rs m10,08960,021 16.8%  
Other income Rs m2572,988 8.6%   
Total revenues Rs m10,34663,009 16.4%   
Gross profit Rs m-79213,493 -5.9%  
Depreciation Rs m3614,086 8.8%   
Interest Rs m2,7563,085 89.4%   
Profit before tax Rs m-3,6539,310 -39.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m1252,529 4.9%   
Profit after tax Rs m-656,781 -1.0%  
Gross profit margin %-7.822.5 -34.9%  
Effective tax rate %-3.427.2 -12.6%   
Net profit margin %-0.611.3 -5.7%  
BALANCE SHEET DATA
Current assets Rs m9,24052,623 17.6%   
Current liabilities Rs m9,99852,022 19.2%   
Net working cap to sales %-7.51.0 -749.4%  
Current ratio x0.91.0 91.4%  
Inventory Days Days46120 38.7%  
Debtors Days Days6076 78.6%  
Net fixed assets Rs m10,12485,016 11.9%   
Share capital Rs m206846 24.3%   
"Free" reserves Rs m5,58245,376 12.3%   
Net worth Rs m7,73446,222 16.7%   
Long term debt Rs m4,88941,115 11.9%   
Total assets Rs m22,882142,432 16.1%  
Interest coverage x-0.34.0 -8.1%   
Debt to equity ratio x0.60.9 71.1%  
Sales to assets ratio x0.40.4 104.6%   
Return on assets %11.86.9 169.8%  
Return on equity %-0.814.7 -5.8%  
Return on capital %22.314.2 157.2%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m30714,580 2.1%   
Fx outflow Rs m1253,600 3.5%   
Net fx Rs m18110,980 1.7%   
CASH FLOW
From Operations Rs m11,7548,942 131.5%  
From Investments Rs m-561-47,070 1.2%  
From Financial Activity Rs m-6,76234,174 -19.8%  
Net Cashflow Rs m4,432-3,655 -121.3%  

Share Holding

Indian Promoters % 39.6 71.5 55.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 7.0 106.8%  
FIIs % 16.8 12.6 133.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 8.8 410.2%  
Shareholders   16,479 26,511 62.2%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   DR. REDDYS LAB  STERLING BIOTECH  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  IPCA LABS  

Compare ELDER PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Marginally Lower; FMCG & IT Stocks Witness Losses(Closing)

After opening the day on a positive note today, Indian share markets witnessed losses thereafter and ended their trading session marginally lower.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 10.7% (Quarterly Result Update)

Jun 1, 2018 | Updated on Jun 1, 2018

For the quarter ended March 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 10.7% YoY). Sales on the other hand came in at Rs 17 bn (up 20.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 8-QTR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS